Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Enrolling by invitation1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

enrolling_by_invitation150%
active_not_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
enrolling_by_invitationphase_2

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

NCT06544798
active_not_recruitingphase_1

Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

NCT02446249

Clinical Trials (2)

Showing 2 of 2 trials
NCT06544798Phase 2

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

Enrolling By Invitation
NCT02446249Phase 1

Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

Active Not Recruiting

All 2 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
2